{"nctId":"NCT01378273","briefTitle":"Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)","startDateStruct":{"date":"2013-12"},"conditions":["Extreme Prematurity"],"count":941,"armGroups":[{"label":"Control","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Control"]},{"label":"Epo 1000 U/kg followed by 400 U/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Epo"]}],"interventions":[{"name":"Epo","otherNames":["Epotin","Erythropoietin"]},{"name":"Control","otherNames":["Saline"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. NICU inpatients between 24-0/7 and 27-6/7 weeks of gestation\n2. Less than twenty four hours of age\n3. Parental informed consent\n\nExclusion Criteria:\n\n1. Major life-threatening anomalies (brain, cardiac, chromosomal anomalies)\n2. Hematologic crises such as DIC, or hemolysis due to blood group incompatibilities\n3. Polycythemia (hematocrit \\> 65)\n4. Congenital infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"24 Weeks","maximumAge":"27 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Death or Severe Neurodevelopmental Impairment (NDI) at 22-26 Months Corrected Age","description":"Severe NDI was defined as Bayley Scales of infant Development, 3rd edition composite motor score or composite cognitive score \\<70. This instrument is normed at 100 with standard deviation of 15.\n\nCerebral palsy was classified as hemiplegia, diplegia, or quadriplegia, and severity was determined according to the Gross Motor Function Classification System (GMFCS) (levels range from 0 \\[no impairment\\] to 5 \\[most severe impairment\\]). Severe cerebral palsy was defined as a GMFCS level higher than 2.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Serious Adverse Events (SAE)","description":"Serious adverse events were prespecified. These included any symptomatic thrombosis involving a major vessel, unrelated to an infusion catheter requiring anticoagulation therapy, hematocrit level \\>65% or an increase of â‰¥15% in hematocrit in the absence of a preceding blood transfusion, hypertension (defined by receipt of antihypertensive therapy for more than 1 month, discharge with medication, or both), severe pulmonary hemorrhage, severe necrotizing enterocolitis (defined as Bell's stage 2b or 3), severe retinopathy of prematurity resulting in laser surgery or bevacizumab therapy, severe sepsis (defined as culture-proven bacterial or fungal sepsis resulting in blood-pressure support or substantive new respiratory support), grade 3 or 4 intracranial hemorrhage, cardiac arrest that did not result in death, and death.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"284","spread":null},{"groupId":"OG001","value":"282","spread":null}]}]}]},{"type":"SECONDARY","title":"Imaging","description":"Brain MRI at 36 weeks PMA. Injury scoring was done using a modified scoring system of Kidokoro, with higher scores indicating greater brain injury. Scoring Range: 0-39","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"2.6"},{"groupId":"OG001","value":"3.8","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Biomarkers","description":"Plasma Epo concentrations were measured in both groups within the first 24 h after birth before study drug administration (baseline), 30 minutes after study drug administration on day 7 (peak Epo concentration) and 30 minutes before study drug on day 9 (trough Epo) and a random level on day 14 after transition to subcutaneous dosing.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"2,907","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"15.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":284,"n":460},"commonTop":["Blood transfusion","Retinopathy of Prematurity (all grades)","Treated patent ductus arteriosus","Intracranial hemorrhage (all grades)","Bronchopulmonary dysplasia"]}}}